Premium
Private equity major ChrysCapital has hiked its holding in drug-maker Ipca Laboratories Ltd by shelling out close to $20 million more, it is learnt. Its additional investment came at a time when Ipca has been battling regulator challenges starting with an inspection observation by US FDA in mid-2014 leading to ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
